Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically confirmed, unresectable stage IV non-squamous non small cell lung cancer (NSCLC) * Radiographically evaluable disease (measurable or non-measurable) per RECIST 1.1 with modifications * Adequate hematological, renal, and hepatic function, normal coagulation profile, calculated CrCL ≥ 45 mL/min * Other criteria may apply Exclusion Criteria: * Any prior chemotherapy or targeted therapy for non-squamous NSCLC * Subjects with adenosquamous histology or any histology subtype containing greater than 10% squamous cells * Subjects with an epidermal growth factor receptor (EGFR) mutation sensitive to treatment with a tyrosine kinase inhibitor (TKI) * Subjects with known anaplastic lymphoma kinase (EML4-ALK) translocations * History or presence of central nervous system metastases * Central (chest) radiation therapy within 28 days prior to enrollment/randomization, radiation therapy to any other site(s) within 14 days prior to enrollment/randomization * History of pulmonary hemorrhage or gross hemoptysis within 6 months * History of arterial or venous thromboembolism within 12 months * History of clinically significant bleeding within 6 months * Clinically significant cardiovascular disease within 12 months * Other criteria may apply